{"id":13382,"date":"2023-07-25T04:30:00","date_gmt":"2023-07-25T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-presente-ses-resultats-financiers-du-premier-semestre-2023-et-fait-le-point-sur-ses-activites\/"},"modified":"2023-07-25T04:30:00","modified_gmt":"2023-07-25T08:30:00","slug":"dbv-technologies-presente-ses-resultats-financiers-du-premier-semestre-2023-et-fait-le-point-sur-ses-activites","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-presente-ses-resultats-financiers-du-premier-semestre-2023-et-fait-le-point-sur-ses-activites\/","title":{"rendered":"DBV Technologies pr\u00e9sente ses r\u00e9sultats financiers du premier semestre 2023 et fait le point sur ses activit\u00e9s"},"content":{"rendered":"<div class=\"pr-date-globe\">July 25, 2023 16:30 ET<\/div>\n<p align=\"right\">Montrouge, France, le 25 juillet (22h30 CET)<\/p>\n<p align=\"justify\"><strong>DBV Technologies<\/strong> <strong>pr\u00e9sente ses r\u00e9sultats financiers <\/strong><strong>du<\/strong> <strong>premier semestre<\/strong><strong> 202<\/strong><strong>3<\/strong> <strong>et <\/strong><strong>fait<\/strong><strong> le point sur ses activit\u00e9s <\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq Stock Market : DBVT), une soci\u00e9t\u00e9 biopharmaceutique au stade clinique, a annonc\u00e9 aujourd\u2019hui que la soci\u00e9t\u00e9 organisera une conf\u00e9rence t\u00e9l\u00e9phonique et une webcast audio en direct le lundi 31 juillet 2023 \u00e0 23h00 (CEST) afin de pr\u00e9senter les r\u00e9sultats financiers du premier semestre 2023 et de faire le point sur ses activit\u00e9s.<\/p>\n<p align=\"justify\">Les participants peuvent acc\u00e9der \u00e0 cet \u00e9v\u00e8nement via les num\u00e9ros de t\u00e9l\u00e9conf\u00e9rence ci-dessous et en demandant \u00e0 rejoindre l\u2019appel DBV Technologies&nbsp;:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left;\">\u00c9tats-Unis : 1-844-481-2866 <\/li>\n<li style=\"text-align:justify;\">International: +1-412-317-1859&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<\/ul>\n<p align=\"justify\">L&rsquo;appel sera diffus\u00e9 en direct sur le site web de la soci\u00e9t\u00e9, dans la section \u00ab\u00a0Investisseurs et Presse\u00a0\u00bb : <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KW4boMTmmsBIjlPcZU6HqsZNE1pt0eP0G3uuNseDFBwRX8yaElPZV7R7pICNe7GC2hI8jMXSGIBDoJNQiGHL52JeGgZqFGsdi880yiBCU3CCsQR-S59CBH_rlpbuCBksd7Uu_lHSM43wPSKvVupF_NzTXceBKerA3RFty3bZXo0yX4JvVk69qajYSESOwmoo\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.dbv-technologies.com\/fr\/investor-relations\/<\/a>. Une rediffusion de la pr\u00e9sentation sera \u00e9galement disponible sur le site web de DBV apr\u00e8s l&rsquo;\u00e9v\u00e9nement.<\/p>\n<p align=\"justify\"><strong>A<\/strong><strong> propos de<\/strong><strong> DBV Technologies<\/strong><br \/>DBV Technologies d\u00e9veloppe Viaskin\u2122, une plateforme technologique exclusive exp\u00e9rimentale avec de vastes champs d\u2019applications potentielles en immunoth\u00e9rapie. Viaskin\u2122, utilise l\u2019immunoth\u00e9rapie par voie \u00e9picutan\u00e9e, ou EPIT\u2122, qui est la m\u00e9thode d\u00e9velopp\u00e9e par DBV pour administrer des composes biologiquement actifs au syst\u00e8me immunitaire \u00e0 travers une peau intacte. Avec cette nouvelle cat\u00e9gorie de produits candidats non invasifs, la Soci\u00e9t\u00e9 s\u2019attache \u00e0 transformer en toute s\u00e9curit\u00e9 la prise en charge des patients souffrant d\u2019allergies alimentaires. Les programmes de DBV Technologies relatifs aux allergies alimentaires comprennent notamment des essais cliniques en cours sur Viaskin\u2122 Peanut. DBV Technologies a un si\u00e8ge social mondial \u00e0 Montrouge (France) et une structure op\u00e9rationnelle en Am\u00e9rique du Nord \u00e0 Basking Ridge, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris (mn\u00e9monique : DBV, Code ISIN : FR0010417345), tandis que les ADS de la Soci\u00e9t\u00e9 (chacune repr\u00e9sentant la moiti\u00e9 d\u2019une action ordinaire) sont n\u00e9goci\u00e9es sur le Nasdaq Global Select Market (mn\u00e9monique : DBVT).<\/p>\n<p align=\"justify\"><strong>Contact <\/strong><strong>i<\/strong><strong>nvestisseurs<\/strong><br \/>Katie Matthews<br \/>DBV Technologies<br \/>+1 857-529-2363<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qWxbBJ8HmMfdAjO8EacUoIHx21vqc_iLXyXpX3XrjoBCSe15R9ophQMU8OYzWEfZJ2cpksFbPA2PWxMCvNRutk2zVSj0UtzH91-DfdkrCKlzQ7wlhZMbtsaQpGXOfLSNTMHRRA7SQ9KSiwEGWfhu2A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.mattthews@dbv-technologies.com\">katie.mattthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact m\u00e9dias<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/>+1&nbsp;646-842-2393<\/p>\n<p align=\"justify\">angela.marcucci@dbv-technologies.com<\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=hwoOe1ubenqBVCo6PA6n2hxsgkcyQgIDBQCyaKr7UQf7YwiaoMfpEXtqBuLFv1J7A4ua_0cYKN5UusGTyhnSY8qIEtzl62XZP3YPpTnoGckIUR6l99oz4G2wlIqkE3J4UyqbonEtVHGDC2aqLLkNEiDJTjuloSwfuAeLbNacIHg=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/MzM4NmUxNWYtYzRhOS00ZDlkLWIyODUtZDExZDhmZmUzNmJkLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">        <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-13382","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13382\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=13382"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=13382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}